Aligos Therapeutics, Inc.

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Versant Vantage I, L.P.. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Versant Vantage I, L.P. har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:LVTX / LAVA Therapeutics N.V. 10% Owner 532.870
US:GLUE / Monte Rosa Therapeutics, Inc. 10% Owner 1.573.453
US:BDTX / Black Diamond Therapeutics, Inc. 10% Owner 3.726.341
10% Owner 148.312
US:OYST / Oyster Point Pharma Inc 10% Owner 0
US:RPTX / Repare Therapeutics Inc. 10% Owner 0
US:ALGS / Aligos Therapeutics, Inc. 10% Owner 0
10% Owner 0
US:APRE / Aprea Therapeutics, Inc. 10% Owner 0
US:PASG / Passage Bio, Inc. 10% Owner 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Versant Vantage I, L.P.. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb ALGS / Aligos Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-10-20 ALGS Versant Venture Capital VI, L.P. 200.000 15,0000 8.000 375,0000 3.000.000 92 34.94 -2.720.480 -90,68

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ALGS / Aligos Therapeutics, Inc. Insider Trades
Insidersalg ALGS / Aligos Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ALGS / Aligos Therapeutics, Inc. Insider Trades
Insiderkøb APRE / Aprea Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-10-07 APRE Versant Vantage I, L.P. 333.333 15,0000 16.667 300,0000 4.999.995 81 990.6 11.509.345 230,19

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APRE / Aprea Therapeutics, Inc. Insider Trades
Insidersalg APRE / Aprea Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APRE / Aprea Therapeutics, Inc. Insider Trades
Insiderkøb BDTX / Black Diamond Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-02-03 BDTX Versant Venture Capital VI, L.P. 79.013 19,0000 79.013 19,0000 1.501.247 140 44.8 2.038.535 135,79
2020-02-03 BDTX Versant Venture Capital VI, L.P. 23.560 19,0000 23.560 19,0000 447.640
2020-02-03 BDTX Versant Venture Capital VI, L.P. 396.082 19,0000 396.082 19,0000 7.525.558
2020-02-03 BDTX Versant Venture Capital VI, L.P. 396.081 19,0000 396.081 19,0000 7.525.539

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BDTX / Black Diamond Therapeutics, Inc. Insider Trades
Insidersalg BDTX / Black Diamond Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-08-28 BDTX Versant Venture Capital VI, L.P. 221.600 6,3202 221.600 6,3202 1.400.556 223 1.2500 -1.123.556 -80,22

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BDTX / Black Diamond Therapeutics, Inc. Insider Trades
Insiderkøb GLUE / Monte Rosa Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-06-28 GLUE Versant Venture Capital VI, L.P. 157.895 19,0000 157.895 19,0000 3.000.005 67 42.21 3.664.743 122,16

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insidersalg GLUE / Monte Rosa Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-10-29 GLUE Versant Venture Capital VI, L.P. 52.305 9,0815 52.305 9,0815 475.008 197 3.7000 -281.478 -59,26
2024-10-29 GLUE Versant Venture Capital VI, L.P. 15.600 9,4098 15.600 9,4098 146.793
2024-10-28 GLUE Versant Venture Capital VI, L.P. 89.990 9,6593 89.990 9,6593 869.240
2024-09-20 GLUE Versant Venture Capital VI, L.P. 1.132.566 6,5296 1.132.566 6,5296 7.395.203
2024-09-13 GLUE Versant Venture Capital VI, L.P. 9.269 6,1603 9.269 6,1603 57.100
2024-09-12 GLUE Versant Venture Capital VI, L.P. 16.047 6,0017 16.047 6,0017 96.309
2024-09-11 GLUE Versant Venture Capital VI, L.P. 541.897 6,0000 541.897 6,0000 3.251.382

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insiderkøb LVTX / LAVA Therapeutics N.V. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insidersalg LVTX / LAVA Therapeutics N.V. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2025-09-18 LVTX Versant Venture Capital VI, L.P. 366.111 1,4418 366.111 1,4418 527.859 0 1.4700 10.325 1,96
2025-09-18 LVTX Versant Venture Capital VI, L.P. 228.791 1,4418 228.791 1,4418 329.871
2025-09-17 LVTX Versant Venture Capital VI, L.P. 362.806 1,4892 362.806 1,4892 540.291
2025-09-17 LVTX Versant Venture Capital VI, L.P. 226.726 1,4892 226.726 1,4892 337.640
2025-09-16 LVTX Versant Venture Capital VI, L.P. 307.707 1,5332 307.707 1,5332 471.776
2025-09-16 LVTX Versant Venture Capital VI, L.P. 192.293 1,5332 192.293 1,5332 294.824

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insiderkøb PASG / Passage Bio, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-03-03 PASG Versant Venture Capital VI, L.P. 225.000 18,0000 11.250 360,0000 4.050.000 112 36.07 -3.644.212 -89,98

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PASG / Passage Bio, Inc. Insider Trades
Insidersalg PASG / Passage Bio, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PASG / Passage Bio, Inc. Insider Trades
Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-06-23 RPTX Versant Vantage I, L.P. 150.000 20,0000 150.000 20,0000 3.000.000 198 44.46 3.669.000 122,30
2020-06-23 RPTX Versant Vantage I, L.P. 100.000 20,0000 100.000 20,0000 2.000.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2022-06-03 RPTX Versant Vantage I, L.P. 250.000 12,2517 250.000 12,2517 3.062.925 311 8.6300 -905.425 -29,56
2022-06-03 RPTX Versant Vantage I, L.P. 438.795 12,2517 438.795 12,2517 5.375.985
2022-06-03 RPTX Versant Vantage I, L.P. 13.199 12,2517 13.199 12,2517 161.710
2022-06-03 RPTX Versant Vantage I, L.P. 14.611 12,2517 14.611 12,2517 179.010
2022-06-03 RPTX Versant Vantage I, L.P. 33.395 12,2517 33.395 12,2517 409.146

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Versant Vantage I, L.P. som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-09-18 2025-09-18 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -228.791 532.870 -30,04 1,44 -329.871 768.292
2025-09-18 2025-09-18 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -366.111 2.370.533 -13,38 1,44 -527.859 3.417.834
2025-09-18 2025-09-17 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -226.726 761.661 -22,94 1,49 -337.640 1.134.266
2025-09-18 2025-09-17 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -362.806 2.736.644 -11,71 1,49 -540.291 4.075.410
2025-09-18 2025-09-16 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -192.293 988.387 -16,29 1,53 -294.824 1.515.395
2025-09-18 2025-09-16 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -307.707 3.099.450 -9,03 1,53 -471.776 4.752.077
2025-02-06 3 LVTX LAVA Therapeutics NV
Common Shares
3.407.157
2025-02-06 3 LVTX LAVA Therapeutics NV
Common Shares
1.180.680
2024-10-30 2024-10-29 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -15.600 1.573.453 -0,98 9,41 -146.793 14.805.878
2024-10-30 2024-10-29 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -52.305 1.589.053 -3,19 9,08 -475.008 14.430.985
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -5.454 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 5.454 5.454
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -5.499 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 5.499 5.499
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -366.590 1.641.358 -18,26
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -17.595 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 17.595 17.595
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -20.397 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 20.397 20.397
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -1.019.867 4.079.469 -20,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -89.990 2.007.948 -4,29 9,66 -869.240 19.395.372
2024-09-24 2024-09-20 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -1.132.566 5.099.336 -18,17 6,53 -7.395.203 33.296.624
2024-09-13 2024-09-13 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -9.269 6.231.902 -0,15 6,16 -57.100 38.390.386
2024-09-13 2024-09-12 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -16.047 6.241.171 -0,26 6,00 -96.309 37.457.636
2024-09-13 2024-09-11 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -541.897 6.257.218 -7,97 6,00 -3.251.382 37.543.308
2024-08-30 2024-08-28 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale -221.600 3.726.341 -5,61 6,32 -1.400.556 23.551.220
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 148.312 148.312
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 2.531 2.531
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 391.785 391.785
2024-04-04 3 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
375.535
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -1.003.658 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -2.465 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -414.607 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -2.236.888 0 -100,00
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -10.099 0 -100,00
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 10.099 10.099
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -46.753 64.731 -41,94
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -141.103 0 -100,00
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.419 141.103 3,23
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -20.454 28.322 -41,93
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 3.992 136.684 3,01
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -18.478 25.587 -41,93
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 132.692 132.692
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -614.315 850.560 -41,94
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -33.395 111.484 -23,05 12,25 -409.146 1.365.869
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -14.611 48.776 -23,05 12,25 -179.010 597.589
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -13.199 44.065 -23,05 12,25 -161.710 539.871
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -438.795 1.464.875 -23,05 12,25 -5.375.985 17.947.209
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -250.000 2.344.451 -9,64 12,25 -3.062.925 28.723.510
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -1.261 2.465 -33,84
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -51.556 0 -100,00
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 51.556 51.556
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -200.213 414.607 -32,56
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -1.261 3.726 -25,29
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -51.556 0 -100,00
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 51.556 51.556
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -200.213 614.820 -24,57
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -1.531 4.987 -23,49 15,09 -23.109 75.273
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -242.943 815.033 -22,96 15,09 -3.666.957 12.302.027
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -1.912 6.518 -22,68 14,63 -27.978 95.376
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -303.614 1.057.976 -22,30 14,63 -4.442.693 15.481.045
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -2.260 0 -100,00
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 2.260 2.260
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -2.279 0 -100,00
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 2.279 2.279
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -152.071 231.211 -39,68
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series C convertible preferred stock
C - Conversion -2.699.328 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock
C - Conversion -4.150.000 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock
C - Conversion -3.000.000 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series A convertible preferred stock
C - Conversion -20.004.280 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
P - Purchase 157.895 2.097.938 8,14 19,00 3.000.005 39.860.822
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
C - Conversion 1.940.043 1.940.043
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
C - Conversion 6.515.869 6.799.115 2.300,43
2021-06-23 3 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
283.246
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.119 0 -100,00
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.119 1.119
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.128 0 -100,00
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.128 1.128
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -75.000 383.282 -16,37
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -2.018 8.430 -19,31
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -82.486 0 -100,00
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 82.486 82.486
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -320.340 1.361.590 -19,05
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -3.473 0 -100,00
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 3.473 3.473
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -16.079 144.879 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -48.528 0 -100,00
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.520 48.528 3,23
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -7.035 63.387 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.373 47.008 3,01
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -6.355 57.264 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 45.635 45.635
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -211.277 1.903.670 -9,99
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -1.990 10.448 -16,00
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -82.491 0 -100,00
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 82.491 82.491
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -320.368 1.681.930 -16,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -5.607 0 -100,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 5.607 5.607
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -6.500 0 -100,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 6.500 6.500
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -325.000 2.236.888 -12,69
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 458.282 -9,84
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.176 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.176 5.176
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -6.000 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 6.000 6.000
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -300.000 2.594.451 -10,36
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 508.282 -8,96
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.313 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.313 4.313
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.000 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.000 5.000
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -250.000 2.894.451 -7,95
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.328 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.328 4.328
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -20.037 160.958 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -60.472 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.893 60.472 3,23
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -8.766 70.422 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.711 58.579 3,01
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -7.919 63.619 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 56.868 56.868
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -263.278 2.114.947 -11,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 558.282 -8,22
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.744 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.744 4.744
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.500 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.500 5.500
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -275.000 3.144.451 -8,04
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.388 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.388 1.388
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -11.688 180.995 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -35.276 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.105 35.276 3,23
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -5.113 79.188 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 998 34.171 3,01
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -4.620 71.538 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 33.173 33.173
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -153.579 2.378.225 -6,07
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -21.707 192.683 -10,13
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -9.497 84.301 -10,12
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -8.579 76.158 -10,12
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -285.217 2.531.804 -10,12
2020-12-16 2020-12-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -307 0 -100,00
2020-12-16 2020-12-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 307 307
2020-12-16 2020-12-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -310 0 -100,00
2020-12-16 2020-12-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 310 310
2020-12-16 2020-12-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -20.784 822.140 -2,47
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -463 0 -100,00
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 463 463
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -467 0 -100,00
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 467 467
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -31.175 842.924 -3,57
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -200 874.099 -0,02 34,16 -6.833 29.863.243
2020-12-01 2020-11-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -10.193 874.299 -1,15 33,13 -337.680 28.964.302
2020-12-01 2020-11-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -6.797 0 -100,00
2020-12-01 2020-11-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 6.797 6.797
2020-12-01 2020-11-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -7.880 0 -100,00
2020-12-01 2020-11-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 7.880 7.880
2020-12-01 2020-11-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -394.000 3.947.941 -9,07
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -3.316 0 -100,00
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 2.488 3.316 300,48
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -46.121 380.942 -10,80
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 828 828
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -154.671 1.277.541 -10,80
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -1.258 0 -100,00
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.258 1.258
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -1.269 0 -100,00
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.269 1.269
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -84.462 884.492 -8,72
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -8.223 0 -100,00
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 8.223 8.223
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -9.533 0 -100,00
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 9.533 9.533
2020-11-25 2020-11-23 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -476.659 4.341.941 -9,89
2020-11-23 2020-11-19 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -114.854 4.818.600 -2,33 33,01 -3.791.331 159.061.986
2020-11-23 2020-11-19 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -15.163 968.954 -1,54 33,01 -500.531 31.985.172
2020-11-19 2020-11-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -473 4.933.454 -0,01 33,09 -15.653 163.266.740
2020-11-19 2020-11-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -63 984.117 -0,01 33,09 -2.085 32.568.171
2020-11-19 2020-11-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -3.705 4.933.927 -0,08 33,05 -122.450 163.065.301
2020-11-19 2020-11-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -489 984.180 -0,05 33,05 -16.161 32.526.952
2020-11-17 2020-11-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -177 4.937.632 0,00 33,01 -5.843 163.003.576
2020-11-17 2020-11-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -23 984.669 0,00 33,01 -759 32.506.385
2020-11-17 2020-11-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.502 4.937.809 -0,03 34,53 -51.865 170.506.989
2020-11-17 2020-11-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.473 4.939.311 -0,05 33,31 -82.388 164.552.652
2020-11-17 2020-11-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -198 984.692 -0,02 34,53 -6.837 34.002.301
2020-11-17 2020-11-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -327 984.890 -0,03 33,31 -10.894 32.811.512
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -353 4.941.784 -0,01 35,15 -12.408 173.697.777
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -9.450 4.942.137 -0,19 34,39 -325.012 169.973.929
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -3.976 4.951.587 -0,08 33,48 -133.106 165.766.259
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -47 985.217 0,00 35,15 -1.652 34.629.195
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.248 985.264 -0,13 34,39 -42.922 33.885.988
2020-11-13 2020-11-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -524 986.512 -0,05 33,48 -17.542 33.025.857
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -4.282 0 -100,00
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 3.211 4.282 299,81
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -59.534 427.063 -12,23
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.071 1.071
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -199.652 1.432.212 -12,23
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -11.918 0 -100,00
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 11.918 11.918
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -13.816 0 -100,00
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 13.816 13.816
2020-11-13 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -690.814 4.955.563 -12,23
2020-11-12 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -9.027 5.646.377 -0,16 34,94 -315.378 197.268.603
2020-11-12 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.119 5.655.404 -0,04 33,86 -71.748 191.489.717
2020-11-12 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.191 987.036 -0,12 34,94 -41.610 34.484.274
2020-11-12 2020-11-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -280 988.227 -0,03 33,86 -9.481 33.460.971
2020-11-12 2020-11-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -12.433 5.657.523 -0,22 34,14 -424.510 193.169.334
2020-11-12 2020-11-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -11.388 5.669.956 -0,20 33,48 -381.245 189.817.653
2020-11-12 2020-11-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.642 988.507 -0,17 34,14 -56.064 33.751.385
2020-11-12 2020-11-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.503 990.149 -0,15 33,48 -50.317 33.148.010
2020-11-10 2020-11-09 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -5.565 5.681.344 -0,10 33,06 -183.954 187.800.235
2020-11-10 2020-11-09 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -735 991.652 -0,07 33,06 -24.296 32.779.652
2020-11-10 2020-11-06 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.738 5.686.909 -0,05 33,13 -90.706 188.398.765
2020-11-10 2020-11-06 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -362 992.387 -0,04 33,13 -11.993 32.876.293
2020-11-06 2020-11-05 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -7.816 5.689.647 -0,14 33,15 -259.079 188.596.436
2020-11-06 2020-11-05 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.032 992.749 -0,10 33,15 -34.208 32.906.949
2020-11-06 2020-11-04 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.208 5.697.463 -0,04 33,14 -73.164 188.789.425
2020-11-06 2020-11-04 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -292 993.781 -0,03 33,14 -9.676 32.929.629
2020-10-28 2020-10-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -707 5.699.671 -0,01 33,03 -23.354 188.274.382
2020-10-28 2020-10-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -93 994.073 -0,01 33,03 -3.072 32.836.716
2020-10-28 2020-10-26 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -7.158 5.700.378 -0,13 33,30 -238.394 189.848.809
2020-10-28 2020-10-26 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -945 994.166 -0,09 33,30 -31.473 33.110.301
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -198.485 0 -100,00
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -85.065 0 -100,00
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Series B-1 Preferred Stock
C - Conversion -463.959 0 -100,00
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Series B-1 Preferred Stock
C - Conversion -198.839 0 -100,00
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -2.145.991 0 -100,00
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
P - Purchase 200.000 862.444 30,19 15,00 3.000.000 12.936.660
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
C - Conversion 198.485 662.444 42,78
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
C - Conversion 463.959 463.959
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
C - Conversion 85.065 2.429.895 3,63
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
C - Conversion 198.839 2.344.830 9,27
2020-10-20 2020-10-20 4 ALGS Aligos Therapeutics, Inc.
Common Stock
C - Conversion 2.145.991 2.145.991
2020-10-20 2020-10-19 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -3.739 5.707.536 -0,07 33,43 -124.998 190.808.065
2020-10-20 2020-10-19 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -494 995.111 -0,05 33,43 -16.515 33.267.456
2020-10-20 2020-10-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -7.697 5.711.275 -0,13 33,57 -258.410 191.743.493
2020-10-20 2020-10-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.016 995.605 -0,10 33,57 -34.110 33.425.248
2020-10-20 2020-10-15 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.473 5.718.972 -0,04 33,03 -81.694 188.922.237
2020-10-20 2020-10-15 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -327 996.621 -0,03 33,03 -10.802 32.922.677
2020-10-15 2020-10-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -4.859 5.721.445 -0,08 33,09 -160.787 189.326.048
2020-10-15 2020-10-14 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -642 996.948 -0,06 33,09 -21.244 32.989.607
2020-10-15 2020-10-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -10.370 5.726.304 -0,18 33,39 -346.271 191.210.453
2020-10-15 2020-10-13 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.369 997.590 -0,14 33,39 -45.713 33.311.126
2020-10-13 2020-10-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -353 5.736.674 -0,01 33,11 -11.687 189.926.934
2020-10-13 2020-10-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -47 998.959 0,00 33,11 -1.556 33.073.035
2020-10-13 2020-10-09 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -3.357 5.737.027 -0,06 33,67 -113.018 193.145.619
2020-10-13 2020-10-09 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -443 999.006 -0,04 33,67 -14.914 33.633.035
2020-10-13 2020-10-08 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -8.502 5.740.384 -0,15 33,68 -286.352 193.339.577
2020-10-13 2020-10-08 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -7.774 5.748.886 -0,14 33,25 -258.461 191.132.638
2020-10-13 2020-10-08 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.122 999.449 -0,11 33,68 -37.790 33.662.042
2020-10-13 2020-10-08 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -1.027 1.000.571 -0,10 33,25 -34.145 33.265.884
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -4.131 0 -100,00
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 3.098 4.131 299,90
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -57.424 486.597 -10,56
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.033 1.033
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -192.576 1.631.864 -10,56
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -588 0 -100,00
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 588 588
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -593 0 -100,00
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 593 593
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -39.608 1.001.598 -3,80
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -24.590 5.756.660 -0,43 33,56 -825.154 193.173.361
2020-10-08 2020-10-07 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -3.246 1.041.206 -0,31 33,56 -108.924 34.939.229
2020-10-08 2020-10-06 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -15.980 5.781.250 -0,28 33,26 -531.477 192.278.016
2020-10-08 2020-10-06 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -2.110 1.044.452 -0,20 33,26 -70.176 34.737.325
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -4.131 0 -100,00
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 3.098 4.131 299,90
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -57.424 544.021 -9,55
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.033 1.033
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -192.576 1.824.440 -9,55
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -1.177 0 -100,00
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.177 1.177
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -1.187 0 -100,00
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.187 1.187
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -79.216 1.046.562 -7,04
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -6.901 0 -100,00
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 6.901 6.901
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -8.000 0 -100,00
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 8.000 8.000
2020-09-21 2020-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -400.000 5.797.230 -6,45
2020-08-20 2020-08-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -5.176 0 -100,00
2020-08-20 2020-08-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 5.176 5.176
2020-08-20 2020-08-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -6.000 0 -100,00
2020-08-20 2020-08-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 6.000 6.000
2020-08-20 2020-08-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other -300.000 6.197.230 -4,62
2020-08-14 2020-08-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -5.176 0 -100,00
2020-08-14 2020-08-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 5.176 5.176
2020-08-14 2020-08-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -6.000 0 -100,00
2020-08-14 2020-08-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 6.000 6.000
2020-08-14 2020-08-12 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -300.000 6.497.230 -4,41
2020-08-12 2020-08-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -6.692 6.797.230 -0,10 33,08 -221.380 224.861.205
2020-08-12 2020-08-11 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -883 1.125.778 -0,08 33,08 -29.211 37.242.200
2020-08-12 2020-08-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -5.492 6.803.922 -0,08 33,04 -181.446 224.789.336
2020-08-12 2020-08-10 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
S - Sale X -725 1.126.661 -0,06 33,04 -23.953 37.222.851
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -1.177 0 -100,00
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.177 1.177
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -1.187 0 -100,00
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.187 1.187
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -79.217 1.127.386 -6,57
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -4.131 0 -100,00
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 3.098 4.131 299,90
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -57.424 601.445 -8,72
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other 1.033 1.033
2020-07-29 2020-07-27 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
J - Other X -192.576 2.017.016 -8,72
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Simple Agreement for Future Equity
C - Conversion -333.333 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.245.330 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.745.458 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -14.452.795 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 577.544 577.544
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 3.176.507 3.176.507
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -458.282 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -875.568 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -3.350 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -3.708 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -8.475 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -111.361 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -2.443.883 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -61.791 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -68.398 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -156.335 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -2.054.198 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
P - Purchase 100.000 3.419.451 3,01 20,00 2.000.000 68.389.020
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
P - Purchase 150.000 608.282 32,73 20,00 3.000.000 12.165.640
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 458.282 458.282
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 875.568 3.319.451 35,83
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 3.350 84.737 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 3.708 93.798 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 8.475 214.390 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 111.361 2.817.021 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 2.443.883 2.443.883
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 61.791 81.387 315,32
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 68.398 90.090 315,31
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 156.335 205.915 315,32
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 2.054.198 2.705.660 315,32
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-05-20 2020-05-18 4 APRE Aprea Therapeutics, Inc.
Common Stock
J - Other -1.734 0 -100,00
2020-05-20 2020-05-18 4 APRE Aprea Therapeutics, Inc.
Common Stock
J - Other 1.734 1.734
2020-05-20 2020-05-18 4 APRE Aprea Therapeutics, Inc.
Common Stock
J - Other -1.750 0 -100,00
2020-05-20 2020-05-18 4 APRE Aprea Therapeutics, Inc.
Common Stock
J - Other 1.750 1.750
2020-05-20 2020-05-18 4 APRE Aprea Therapeutics, Inc.
Common Stock
J - Other -116.664 216.669 -35,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series B Preferred Stock
C - Conversion -708.352 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-2 Preferred Stock
C - Conversion -1.049.175 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-1 Preferred Stock
C - Conversion -2.977.242 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
P - Purchase 225.000 933.352 31,76 18,00 4.050.000 16.800.336
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 708.352 708.352
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 1.049.175 4.026.417 35,24
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 2.977.242 2.977.242
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -2.444.382 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.055.960 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -314.873 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.370.833 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.517.940 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -452.630 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.970.572 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -3.851.526 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -1.148.474 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -15.000.000 0 -100,00
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
P - Purchase 396.081 1.206.603 48,87 19,00 7.525.539 22.925.457
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
P - Purchase 396.082 6.809.414 6,18 19,00 7.525.558 129.378.866
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
P - Purchase 23.560 658.869 3,71 19,00 447.640 12.518.511
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
P - Purchase 79.013 2.209.592 3,71 19,00 1.501.247 41.982.248
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 810.522 810.522
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 350.141 2.130.579 19,67
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 104.407 635.309 19,67
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 454.548 6.413.332 7,63
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 503.327 1.780.438 39,41
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 150.085 530.902 39,41
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 653.412 5.958.784 12,32
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 1.277.111 1.277.111
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 380.817 380.817
2020-02-05 2020-02-03 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
C - Conversion 4.973.787 5.305.372 1.500,00
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2020-01-29 3 BDTX Black Diamond Therapeutics, Inc.
Common Stock
663.170
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock
C - Conversion -566.158 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock
C - Conversion -495.388 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.941.500 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.654.359 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -10.420 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 437.500 1.003.658 77,28 16,00 7.000.000 16.058.528
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 566.158 566.158
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 125.000 2.561.888 5,13 16,00 2.000.000 40.990.208
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 495.388 2.436.888 25,52
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 1.941.500 1.941.500
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 27.500 2.002.298 1,39 16,00 440.000 32.036.768
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 1.654.359 1.974.798 516,28
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 10.420 12.438 516,35
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-07 2019-10-07 4 APRE Aprea Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -512.995 0 -100,00
2019-10-07 2019-10-07 4 APRE Aprea Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.993.658 0 -100,00
2019-10-07 2019-10-07 4 APRE Aprea Therapeutics, Inc.
Common Stock
P - Purchase 333.333 333.333 15,00 4.999.995 4.999.995
2019-10-07 2019-10-07 4 APRE Aprea Therapeutics, Inc.
Common Stock
C - Conversion 512.995 2.519.323 25,57
2019-10-07 2019-10-07 4 APRE Aprea Therapeutics, Inc.
Common Stock
C - Conversion 1.993.658 2.006.328 15.735,26
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)